NTLA – intellia therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

NTLA

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/3

03:13 pm

ntla

Rating for NTLA

Low Report

Rating for NTLA

Report

3/3

11:14 am

ntla

Rating for NTLA

Low Report

Rating for NTLA

Report

3/3

10:38 am

ntla

Rating for NTLA

Low Report

Rating for NTLA

Report

3/3

10:38 am

ntla

Rating for NTLA

Low Report

Rating for NTLA

Report

3/3

10:08 am

ntla

Rating for NTLA

Medium Report

Rating for NTLA

Report

3/3

10:08 am

ntla

Rating for NTLA

Medium Report

Rating for NTLA

Report

3/2

03:48 pm

ntla

Rating for NTLA

Low Report

Rating for NTLA

Report

3/2

01:05 pm

ntla

Intellia Therapeutics (NTLA) had its "neutral" rating reaffirmed by Bank of America Corporation.

Low Report

Intellia Therapeutics (NTLA) had its "neutral" rating reaffirmed by Bank of America Corporation.

Report

3/2

01:00 pm

ntla

Intellia Therapeutics (NTLA) was upgraded by William Blair from "market perform" to "outperform".

Low Report

Intellia Therapeutics (NTLA) was upgraded by William Blair from "market perform" to "outperform".

Report

3/2

01:00 pm

ntla

Intellia Therapeutics (NTLA) was upgraded by William Blair from "market perform" to "outperform".

Low Report

Intellia Therapeutics (NTLA) was upgraded by William Blair from "market perform" to "outperform".

Report

3/2

12:39 pm

ntla

Intellia Therapeutics upgraded to Outperform from Market Perform at William Blair

Low Report

Intellia Therapeutics upgraded to Outperform from Market Perform at William Blair

Report

3/2

12:39 pm

ntla

Intellia Therapeutics upgraded to Outperform from Market Perform at William Blair

Low Report

Intellia Therapeutics upgraded to Outperform from Market Perform at William Blair

Report

2/27

08:32 am

ntla

Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.

Low Report

Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.

Report

2/27

08:17 am

ntla

Rating for NTLA

Low Report

Rating for NTLA

Report

1/28

07:19 am

ntla

Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Medium Report

Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.